Hematology Deal Benchmarks
Leukemia, lymphoma, myeloma, sickle cell, and hemophilia deal benchmarks. Benchmarks derived from 54 verified transactions.
54
Total Deals
$649M
Avg Upfront
4
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
16
license
24
acquisition
11
collaboration
3
option
0
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Silence Therapeutics → Hansoh Pharmaceutical mRNAi GOLD platform (siRNA therapies, 3 targets) | option | $16M | — | Jun 2026 |
Vega Therapeutics (Star Therapeutics) → Incyte Late-stage von Willebrand disease drug | acquisition | $1.3B | $2.0B | Jun 2026 |
Agios Pharmaceuticals → Vulcan Experimental blood-disorder drug | license | $10M | $165M | Jun 2026 |
Vega Therapeutics → Incyte factor VIII-independent bleeding disorder program | acquisition | $730M | $2.0B | May 2026 |
Protagonist Therapeutics → Takeda rusfertide | license | $475M | — | Apr 2026 |
Keros Therapeutics → Takeda anemia | license | $200M | $200M | Dec 2024 |
Curon Biopharmaceutical → Merck hematologic_malignancies | acquisition | $700M | $1.3B | Oct 2024 |
Disc Medicine → Novo Nordisk thalassemia | license | $100M | $1.2B | Sep 2024 |
MorphoSys → Novartis myelofibrosis | acquisition | $2.9B | $2.9B | Jan 2024 |
Prime Medicine → Bristol Myers Squibb Prime gene editing CAR-T | collaboration | $110M | $3.6B | Jan 2024 |
Benchmark Your Hematology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 54 verified hematology transactions.
Run Hematology Benchmark